Posted by Michael Wonder on 23 Jul 2025
European Commission approves Imbruvica (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
23 July 2025 - Data from the Phase 3 TRIANGLE study defines the fixed-duration ibrutinib-based regimen as a new standard of care with significantly improved overall survival and failure-free survival versus ASCT.
Janssen-Cilag today announced that the European Commission has approved an indication extension of Imbruvica (ibrutinib) in frontline mantle cell lymphoma.
